NASDAQ$CRMD
CorMedix Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2022.
CorMedix reported a net loss of $7.6 million, or $0.19 per share, for the second quarter of 2022, compared to a net loss of $4.6 million, or $0.12 per share, in the second quarter of 2021. The company's operating expenses increased by approximately 41% to $8.3 million, driven by increases in both SG&A and R&D expenses.
- Net loss for the second quarter of 2022 was $7.6 million, or $0.19 per share.
- Operating expenses increased approximately 41% to $8.3 million compared to Q2 2021.
- R&D expense increased approximately 28% to $3.2 million compared to Q2 2021.
- SG&A expense increased approximately 50% to $5.1 million compared to Q2 2021.
Headline financials
Revenue & EPS history
CorMedix · Revenue · Quarterly
$21.3K
Forward guidance
CorMedix anticipates having sufficient cash to fund operations through at least the next four quarters and is focused on obtaining FDA approval of the DefenCath NDA as quickly as possible.
Tailwinds
- Sufficient cash on hand to fund operations through at least the next four quarters.
- Team is focused on obtaining FDA approval of the DefenCath NDA as quickly as possible.
- Confident in the pathway forward to an FDA approval.
- Aiming to deliver on commitment to patients.
- Working to obtain regulatory approval for manufacturing with Alcami.
Headwinds
- Disappointed that they will not receive FDA approval on the PDUFA date.
- FDA approval is contingent on either existing CMO and API supplier obtaining compliance clearance.
- Approval is also dependent on obtaining regulatory approval for manufacturing with Alcami.
- Uncertainty surrounding the Coronavirus pandemic may impact business and operations.
- Ability of the CMO to address the deficiencies identified by the FDA.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2022
-1.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+12.4%
Avg return
30 days after
43%
20 / 47 earnings
Positive
+31.1%
Q3 2022
Best reaction
-31.8%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +4.4% | +16.7% | |
| Q4 2025 | -11.7% | -5.6% | -1.0% | |
| Q3 2025 | +2.1% | -10.8% | +2.7% | |
| Q1 2025 | +23.6% | +29.1% | +46.0% | |
| Q4 2024 | -31.8% | +13.8% | +98.2% | |
| Q3 2024 | -22.4% | -26.1% | -24.0% | |
| Q2 2024 | +27.0% | +36.5% | +83.9% | |
| Q1 2024 | -9.5% | -6.7% | -9.6% | |
| Q4 2023 | +10.8% | +8.2% | +81.5% | |
| Q3 2023 | +7.1% | +28.9% | +10.9% | |
| Q2 2023 | +6.1% | +7.3% | -8.5% | |
| Q1 2023 | -13.9% | -1.5% | +5.2% | |
| Q4 2022 | +13.1% | +16.4% | +35.0% | |
| Q3 2022 | +31.1% | +30.4% | +33.6% | |
| Q2 2022 | +22.8% | +26.6% | +10.1% | |
| Q1 2022 | +7.6% | +25.7% | -3.3% | |
| Q4 2021 | +3.4% | -1.4% | -37.6% | |
| Q3 2021 | +0.4% | -0.4% | -6.0% | |
| Q2 2021 | +7.1% | +4.2% | -21.7% | |
| Q1 2021 | -23.1% | -16.9% | +4.6% | |
| Q4 2020 | +15.0% | +16.1% | -1.4% | |
| Q3 2020 | -0.9% | +5.7% | +61.0% | |
| Q2 2020 | -0.5% | +5.6% | +10.0% | |
| Q1 2020 | -6.9% | -2.7% | +54.2% | |
| Q4 2019 | -22.5% | -31.3% | -3.8% | |
| Q3 2019 | +6.1% | +28.2% | +25.8% | |
| Q2 2019 | -2.8% | -0.6% | -3.6% | |
| Q1 2019 | -7.7% | -0.4% | +8.7% | |
| Q4 2018 | -1.6% | -14.6% | -0.5% | |
| Q3 2018 | -15.5% | +9.1% | +27.3% | |
| Q2 2018 | -21.7% | -25.0% | -1.7% | |
| Q1 2018 | -5.0% | -5.0% | +60.0% | |
| Q4 2017 | -19.4% | -32.3% | -32.3% | |
| Q3 2017 | +3.8% | -9.4% | +5.7% | |
| Q2 2017 | -5.4% | -2.7% | +16.2% | |
| Q1 2017 | -5.8% | -5.8% | -15.4% | |
| Q4 2016 | -12.2% | -22.0% | -40.5% | |
| Q3 2016 | -18.6% | -22.1% | -23.0% | |
| Q2 2016 | -7.1% | -8.4% | +18.8% | |
| Q1 2016 | -11.7% | — | — | |
| Q4 2015 | -5.2% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | — | — | — | |
| Q2 2014 | +5.9% | — | — | |
| Q2 2013 | +24.4% | — | — | |
| Q4 2013 | -1.2% | — | — | |
| Q2 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro